Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next generation sequencing transcriptomic analysis of bone marrow derived macrophages within control, Cbl-/-, Cbl-b -/- and DKO genotypes

ABSTRACT: Next generation sequencing transcriptomic analysis of bone marrow derived macrophages within control, Cbl-/-, Cbl-b -/- and DKO genotypes

PROVIDER: PRJNA540522 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8992790.fastq.gz	Fastqsanger.gz
	SRR8992800.fastq.gz	Fastqsanger.gz
	SRR8992810.fastq.gz	Fastqsanger.gz
	SRR8992820.fastq.gz	Fastqsanger.gz
	SRR8992830.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Next generation sequencing transcriptomic analysis of bone marrow derived macrophages within control, Cbl-/-, Cbl-b -/- and DKO genotypes

Project description:The goal of the transcriptomic profiling is to understand what genes or pathway Cbl and Cbl-b regulate for CSF-1R dependent growth signaling

2019-05-01 | GSE130527 | GEO

Quantitative Analysis of Wild Type CBL, CBL 70Z and Y371S 3T3 Stable Cell Transcriptomes

Project description:Cbl (Casitas B-lineage lymphoma) is a prominent post-translational regulator of protein tyrosine kinases (PTKs) that targets activated receptors for ubiquitination-mediated degradation. However, mutations within its E3 ubiquitin ligase activity rendering RING domain are often not sufficient to induce transformation. Rather, a conserved residue (Y371) within the linker helix region (LHR) of Cbl has been a mutational hotspot in myeloproliferative diseases. Interestingly, phosphorylation of Y371 is a prerequisite for Cbl’s ability to ubiquitinate PTKs. We have previously shown that Y371 mutations affect the conformation of Cbl that can be related to its transformation potential. We wanted to investigate for any additional advantage that the Cbl-Y371 mutants could gain over their wild-type counterpart so as to explain their oncogenicity. In our current study, we wanted to investigate the transcriptome profiles of cells overexpressing WT CBL or CBL-70Z, a well-characterized oncogenic CBL mutant lacking residues 366-382 and Y371S a prevalent MDS/MPN CBL mutant. We found an interesting inverse correlationship between the transcriptome of cells expressing WT CBL and the mutant CBLs. The results from this study can be linked to the oncogenic abilities of the mutant CBLs.

2019-10-20 | GSE121176 | GEO

Comparative analysis of WT CBL and CBL 70Z interactomes.

Project description:Cbl (Casitas B-lineage lymphoma) is a prominent post-translational regulator of protein tyrosine kinases (PTKs) that targets activated receptors for ubiquitination-mediated degradation. However, mutations within its E3 ubiquitin ligase activity rendering RING domain are often not sufficient to induce transformation. Rather, a conserved residue (Y371) within the linker helix region (LHR) of Cbl has been a mutational hotspot in myeloproliferative diseases. Interestingly, phosphorylation of Y371 is a prerequisite for Cblâ€™s ability to ubiquitinate PTKs. We have previously shown that Y371 mutations affect the conformation of Cbl that can be related to its transformation potential. We wanted to investigate for any additional advantage that the Cbl-Y371 mutants could gain over their wild-type counterpart so as to explain their oncogenicity. In our current study, we utilized CBL-70Z, a well-characterized oncogenic CBL mutant lacking residues 366-382 that behave similar to the prevalent MDS/MPN CBL mutants, as an example to explore differences in interactomes between Wild type CBl and CBL 70Z. Any divergent interacting abilities between the two can be used to decipher the mechanism by which the mutants elicit oncogenic transformation.

2021-02-26 | PXD011369 | Pride

Genome wide transcriptional profiling of c-Cbl deficient hematopoietic stem and progenitor cells

Project description:Expression of genes that are differentially expressed between c-Cbl control and c-Cbl mutant hematopoietic stem and progenitor cells were identified through this approach. Interestingly, several leukemia associated genes, particularly transcription factors, were differentially expressed between c-Cbl WT and c-Cbl mutant hematopoietic stem and progenitor cells. Hematopoietic stem and progenitor cells of c-Cbl control and c-Cbl mutant mice were sorted based on their defined immunophenotype. Gene expression studies were performed using Illumina microarray chips.

2010-08-12 | E-GEOD-23564 | biostudies-arrayexpress

Cbl family proteins are required to maintain the proteome homeostasis in mammary epithelial cells

Project description:EGFR degradation is delayed in Cbl, Cbl-b double-deficient MCF10A but EGF stimulation does not enhance their growth. We performed a transcriptome analysis to gain insights into biological consequences of Cbl, Cbl-b loss in mammary epithelial cells. We compared the transcriptome of MCF10A cells expressing shRNA against Cbl and Cbl-b with control shRNA-expressing cells using Affymetrix U133 Plus 2.0. Each sample was prepared in duplicates. Data were analyzed by GSEA.

2016-03-25 | E-GEOD-67301 | biostudies-arrayexpress

Genome wide transcriptional profiling of c-Cbl deficient hematopoietic stem and progenitor cells

2010-08-12 | GSE23564 | GEO

Cbl family proteins are required to maintain the proteome homeostasis in mammary epithelial cells

2016-03-25 | GSE67301 | GEO

Locking CBL in its native conformation presents a novel therapeutic opportunity in mutant CBL-dependent leukaemia (part2)

Project description:Casitas B-lineage lymphoma (CBL) is critical to the negative regulation of receptor protein tyrosine kinases (RTKs). Mutant CBL can act as an adaptor and gain function to cause myeloproliferative diseases. Currently, there is no beneficial treatment available for leukaemia patients with CBL mutations. Using phage-display technique, we identified a peptide inhibitor CBLock that binds a pocket in CBL’s tyrosine kinase binding domain (TKBD) in its native conformation as revealed by a crystal structure. CBLock inhibits proliferation, causes cell cycle arrest and apoptosis in leukaemia cells that harbour CBL mutations. CBLock disrupts the interaction between CBL mutants and RTK/adaptor protein, hindering the gain-of-function of CBL mutants. We find reduced tumour progression and improved survival upon conditional expression of CBLock in a xenograft AML model. CBLock also resulted in reduced FLT3 downstream signalling. Therefore, inhibiting CBL-TKBD in its native state presents a useful therapeutic opportunity in targeting mutant/inactive CBL-dependent leukaemia.

2025-05-06 | PXD051179 | Pride

Quantitative Analysis of Wild Type CBL, CBL 70Z and Y371S 3T3 Stable Cell Transcriptomes

Project description:Quantitative Analysis of Wild Type CBL, CBL 70Z and Y371S 3T3 Stable Cell Transcriptomes

| PRJNA495948 | ENA

Locking CBL in its native conformation presents a novel therapeutic opportunity in mutant CBL-dependent leukaemia (part 1)

2025-05-06 | PXD051178 | Pride